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Objective: This retrospective analysis examined whether diffusion-weighted magnetic resonance imaging might
be as useful as positron emission tomographywith fludeoxyglucose F 18 for (1) discriminating between non–small
cell lung cancer and benign pulmonary nodules and (2) predicting aggressiveness of non–small cell lung cancer.
Methods: Diffusion-weighted magnetic resonance imaging and positron emission tomography were performed
before surgery in 110 patients with 124 pulmonary nodules smaller than 3 cm, including 96 non–small cell lung
cancers and 28 benign nodules. Diffusion of water molecules in magnetic resonance imaging was measured by
minimum value of apparent diffusion coefficient. The criterion standard was the result of histologic diagnosis or
follow-up examination. Sensitivity and specificity for differentiating between cancers and benign nodules were
compared between diffusion-weighted imaging and positron emission tomography. Apparent diffusion coeffi-
cient in diffusion-weighted imaging and fludeoxyglucose F 18 uptake in positron emission tomography were ex-
amined with respect to pathologic tumor stage; lymphatic, vascular and pleural involvements; and histologic
differentiation.
Results: There were no significant differences between diffusion-weighted magnetic resonance imaging and pos-
itron emission tomography in sensitivity or specificity for non–small cell lung cancer. Whereas positron emission
tomography showed significant differences in fludeoxyglucose F 18 uptake between pathologic stages IA versus
IB or more advanced stages; between tumors with and without lymphatic, vascular, or pleural involvement; and
between well-differentiated and moderately or poorly differentiated adenocarcinomas (P<.01–0.001), no signif-
icant differences in apparent diffusion coefficient values in were observed.
Conclusion: Diffusion-weighted magnetic resonance imaging is equivalent to positron emission tomography in
distinguishing non–small cell lung cancer from benign pulmonary nodules but is not as useful for predicting
aggressiveness of non–small cell lung cancer.Recent advances in magnetic resonance (MR) gradient tech-
nology have led to the introduction of diffusion-weighted
MR imaging (DWI), which provides excellent tissue con-
trast through detection of differences in the diffusion of wa-
ter molecules among tissues and is entirely different from
ordinary T1- and T2-weighted MR images. Because the dif-
fusion of water molecules is disturbed by intracellular organ-
elles and macromolecules, any architectural changes in the
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alters the signal intensity on DWI, the apparent diffusion co-
efficient (ADC).1,2 Because malignant tumors are character-
ized by increased cellularity, larger nuclei with more
abundant macromolecular proteins, larger nuclear/cytoplas-
mic ratio, and less extracellular space relative to normal tis-
sues, the diffusion of water molecules in malignant tumors is
restricted, resulting in decreased ADC values and allowing
imaging of malignant tumors by DWI.3,4 To date, the utility
of DWI has been reported for the imaging of brain tumors,5
breast tumors,6 musculoskeletal tumors,7 prostate cancer,8
rectal cancer,9 and lung cancer.10
Positron emission tomography (PET) with fludeoxyglu-
cose F 18 (FDG) has been found to be extremely useful
for discriminating betweenmalignant and benign pulmonary
nodules. Although several authors have compared images
between DWI and PET in a small number of tumors,11,12
there have been few reported comparisons of the sensitivity
and specificity of DWI and FDG-PET for diagnosing malig-
nancy. Recently, we showed DWI to have similar sensitivityardiovascular Surgery c Volume 138, Number 2 439
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ADC ¼ apparent diffusion coefficient
CT ¼ computed tomography
DWI ¼ diffusion-weighted magnetic
resonance imaging
FDG ¼ fludeoxyglucose F 18
FDG-PET ¼ positron emission tomography with
fludeoxyglucose F 18
FN ¼ false-negative result
FP ¼ false-positive result
MR ¼ magnetic resonance
PET ¼ positron emission tomography
ROI ¼ region of interest
SUV ¼ standard uptake value
SUVCR ¼ contrast ratio of standard uptake value
SUVmax ¼ maximum standard uptake value
TE ¼ echo time
TN ¼ true-negative result
TP ¼ true-positive result
TR ¼ repetition time
and a slightly higher specificity than FDG-PET for distin-
guishing between malignant and benign pulmonary nod-
ules.13 Ohno and colleagues14 reported that whole-body
MR imaging with DWI had similar accuracy to FDG-PET
for M-staging in patients with non–small cell lung cancer
(NSCLC).14 FDG-PET has also been reported to aid in as-
sessment of tumor aggressiveness, however, including
tumor stage and intratumoral invasiveness, and thus progno-
sis.15-18 In assessing the relative merits of DWI and FDG-
PET for imaging of NSCLC, the utilities of the examinations
for both diagnosis and evaluation of tumor aggressiveness
should be compared.
In this study, we conducted a retrospective analysis of the
subject data with the following objectives: (1) to examine the
utility of DWI in the differential diagnosis of pulmonary
nodules by comparing the sensitivities and specificities of
DWI and FDG-PET for discriminating between NSCLC
and benign pulmonary nodules, and (2) to compare the util-
ity of DWI and PET in predicting the aggressiveness of
NSCLC. Although our previous study included both pri-
mary and metastatic lung cancers,13 metastatic lung cancers
were excluded in this study to compare the utility of the two
procedures in evaluating the aggressiveness of NSCLC. In
addition, although our previous study included tumors larger
than 3 cm, this study was targeted at NSCLCs smaller than 3
cm to compare the utility in assessing tumor aggressiveness
between DWI and FDG-PET, because FDG uptake is depen-
dent on the tumor size.19440 The Journal of Thoracic and Cardiovascular SuMATERIALS AND METHODS
Eligibility
The examination of both DWI and FDG-PET in patients with lung cancer
was approved by the Ethical Committee of Kumamoto University Hospital
in January 2006. Informed consent was obtained from all patients after they
and their surgeons received explanations of the costs and benefits of the
examinations.
Patients
Between February 2006 and December 2007, a total of 144 patients with
182 pulmonary lesions underwent both FDG-PET and DWI, which were
done within 2 weeks of each other. Of these lesions, 22 lesions larger than
3 cm and 11 metastatic lung cancers were excluded from this study.
Twenty-five lesions with the appearance of pure ground-glass opacity
were also excluded, because all these nodules yielded negative results on
both DWI and PET. After these exclusions, 110 patients with a total of
124 nodules were entered in the study (Table 1). There were 56 men and
54 women, with a mean age of 68  9 years (range 36–82 years). Of the
124 nodules, 106 were diagnosed histologically after surgical resection,
whereas 18 were diagnosed as old inflammation because their sizes were
found on reviewof retrospective chest radiography or computed tomography
(CT) to have been unchanged for more than 2 years. Mean follow-up dura-
tion for these 18 nodules, of which 6 were checked by radiography and the
other 12 by CT, was 41  23 months (range: 24-97 months). Mean size of
these 18 nodules was 1.6  0.6 cm (range 1.0–3.0 cm). None of the 124
lesions had apparent cavitations and calcifications on CT. Long-axis diame-
ters of pulmonary nodules were considered to represent sizes of the lesions.
PET and CT Scanning
Patients were instructed to fast for at least 5 hours before intravenous ad-
ministration of FDG. The dose of FDG administered was 100 mCi/kg (3.7
MBq/kg). PET imaging was performed approximately 60 minutes after in-
travenous administration of FDG with an integrated PET and CT device
(Discovery ST; GE Medical Systems, Milwaukee, Wis) that consisted of
a PET scanner (Advance Nx; GE Medical Systems) and an 8-section CT
scanner (Light Speed Plus; GEMedical Systems). All images were acquired
under shallow-breathing conditions.
The acquisition time for PET in 3-dimensionalmodewas 3minutes per ta-
ble position. CT data were resized from a 5123 512 matrix to a 1283 128
matrix to match the PET data to allow image fusion, and a CT transmission
map was generated. PET image data were reconstructed iteratively with the
ordered subsets expectation maximization algorithm with segmented attenu-
ation correction (4 iterations, 28 subsets) and the CT data. The 3.75-mm thick
transaxial CT images were reconstructed at 3.27-mm intervals (transaxial) for
fusion with the transaxial PET images. The PET, CT, and fused images were
available for review in the axial, coronal, and sagittal planes bymeans of soft-
ware (Xeleris; GE Medical Systems) on a computer workstation.
Diffusion-Weighted Imaging
All MR images were obtained with a 1.5-T superconducting system
(Gyroscan Intera Achieva Nova Dual; Philips Nederland BV Medical Sys-
tems, Eindhoven, The Netherlands). Conventional MR and DWI images
were acquired during the same procedure. The conventional MR images
consisted of a coronal T1-weighted sequence (repetition time [TR] 234
ms, echo time [TE] 4 ms, 1 excitation) and coronal and axial single-shot
spin echo T2-weighted (TR 800 ms, TE 90 ms, 1 excitation) and coronal
and axial short tau inversion recovery (TR 4600 ms, TE 90 ms, inversion
time 160 ms) sequences. The T1-weighted, T2-weighted, and short tau in-
version recovery sequences were acquired at a section thickness of 6 mm
with a 1-mm intersection gap, a 1283 128 matrix, and a 40- to 45-cm field
of view. All images were acquired under shallow-breathing conditions.
DWI was performed in the transverse plane with a spin-echo, echo-pla-
nar imaging sequence with the following parameters: TR 5900 ms, TE 60rgery c August 2009
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b ¼ 1000 s/mm2, field of view 400 mm, matrix size 112 3 100, section
thickness 6 mm, section gap 1 mm, and number of signals acquired 6.
PET Data Analysis
One radiologist (S.S.) with 11 years of radioisotope scintigraphy and
PET experience who was unaware of the patients’ clinical data evaluated
the PET and CT data. After image reconstruction, a 2-dimensional circular
region of interest (ROI) was drawn in a slice after visual detection of the
highest count on the fused CT image. For the lesions with negative or faintly
positive PET findings, the ROI was drawn on the fusion image with the cor-
responding CT. From these ROIs, the standard uptake value (SUV) maxi-
mum (SUVmax) was calculated. The contrast ratio of SUV (SUVCR) was
then calculated as described previously.20,21 Briefly, the values of SUVmax
in the tumor ROI (T) and at the equivalent point in the contralateral normal
lung (N) were measured. The SUVCR was calculated as (TN)/(TþN) in
each lesion as an index of FDG uptake.
DWI Data Analysis
One radiologist (K.K.) with 17 years of MRI experience who was un-
aware of the patients’ clinical data evaluated the MRI image. DWI data
were evaluated semiquantitatively with ADC. The ADC was calculated as
follows: ADC¼[ln(S/S0)]/b, where S is the signal intensity of the ROI ob-
tained through 3 orthogonally oriented DWIs or diffusion trace images, and
b is a gradient b factor with a value of 1000 s/mm2. After image reconstruc-
tion, a 2-dimensional square ROI was drawn in a slice where the lesion was
detected visually with reference to the T2-weighted image on CT. From the
TABLE 1. Characteristics of non-small cell lung cancer and benign
nodules
Non–small cell lung cancer (n ¼ 96)
Size (cm)
Mean  SD 1.6  0.7
Range 1.0–3.0
Histologic type (No.)
Adenocarcinoma 76
Well differentiated 57
Moderately differentiated 14
Poorly differentiated 5
Squamous cell carcinoma 17
Adenosquamous carcinoma 3
Pathologic stage (No.)
IA 75
IB–IV 21
T1N1M0 5
T3N0M0 2
T3N1M0 3
T1N2M0 4
T3N2M0 3
T4N2M0 3
T1N1M1 1
Benign nodules (n ¼ 28)
Size (cm)
Mean  SD 1.5  0.7
Range 1.0–3.0
Type
Acute inflammation 4
Chronic inflammation 20
Hamartoma 2
Others 2The Journal of Thoracic andROI, the minimum ADC value was calculated. The mean ADC was not
used, because the value within the entire tumor might not characterize the
tumor as a result of heterogeneity.22
Determining Cutoffs for ADC and SUVCR
A receiver operating characteristic curve was constructed according to
the ADC and SUVCR with SPSS software (SPSS 15.0 J for Windows,
SPSS Inc, Chicago, Ill), and the cutoffs were determined for discrimination
between benign and malignant lesions. Nodules with less than the ADC cut-
off were defined as positive on DWI. Nodules with more than the SUVCR
cutoff were defined as positive on PET and CT.
Pathologic Analysis
Hematoxylin and eosin and elastica van Gieson staining were performed
on all sections to investigate lymphatic, vascular, and pleural involvements.
Histologic differentiation in adenocarcinoma was classified into well-differ-
entiated, moderately differentiated, and poorly differentiated grades. Pleural
involvement was classified as p0, p1, p2, and p3; that is, a p0 tumor did not
extend beyond the pleural elastic layer, a p1 tumor invaded the visceral pleu-
ral elastic layer but did not reach the pleural surface, a p2 tumor included
tumor exposure on the pleural surface, and a p3 tumor invaded the parietal
pleura or the chest wall. Pathologic tumor stages were based on the TNM
classification of the International Union Against Cancer23: p2 tumors
were classified as T2, p3 tumors were classified as T3, and tumors with in-
trapulmonary metastases within the same lobe were classified as T4.
Analysis of Tumor Aggressiveness
The aggressiveness of NSCLCwas evaluated according to pathologic tu-
mor stage, tumor invasiveness (as determined by lymphatic, vascular, or
pleural involvement), and histologic differentiation of adenocarcinoma, be-
cause these factors are known to be related to prognosis.24,25 To evaluate the
utility of DWI and PET in predicting tumor aggressiveness, the ADC and
the SUVCR were compared between pathologic stage IA versus stage IB
or more advanced stages; between tumors with and without lymphatic, vas-
cular, or pleural involvement; and between well-differentiated and moder-
ately or poorly differentiated adenocarcinomas.
Statistical Analysis
The differences in sensitivity and specificity betweenDWI and PETwere
analyzed with the McNemar test. True-positive (TP), true-negative (TN),
false-positive (FP), and false-negative (FN) results of PET with CT and
DWI images for detecting pulmonary malignancies were compared with
the results of pathologic diagnosis or follow-up examination. Sensitivity
was calculated as TP/(TPþFN), specificity as TN/(TNþFP), and accuracy
as (TPþTN)/total. Positive and negative predictive values were calculated
as TP/(TPþFP) and TN/(TNþFN), respectively, and differences between
DWI and PET were analyzed with the Student t test. The Student t test was
also used to compare size distribution between malignant and benign nod-
ules, ADC and SUVCR at pathological stages IA versus stage IB or more
advanced stages, and ADC and SUVCR between tumors that were or were
not invasive. Statistical analysis was performed with SPSS software. All
values in the text and tables are given as mean  SD.
RESULTS
Histologic type of NSCLC was adenocarcinoma in 76 le-
sions, squamous cell carcinoma in 17, and adenosquamous
carcinoma in 3. Adenocarcinoma was well differentiated
in 57 lesions, moderately differentiated in 14, and poorly
differentiated in 5. Pathologic stage was IA in 75 lesions
and IB or a more advanced stage in 21 (Table 1). Benign
nodules showed acute inflammation in 4 lesions, chronicCardiovascular Surgery c Volume 138, Number 2 441
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There was no significant difference in mean size between
NSCLC and benign lesions.
DWI clearly identified the malignant nodules in a fashion
similar to PET imaging (Figure 1). The receiver operating
FIGURE 1. Lung adenocarcinoma in right lower lobe imaged with com-
puted tomography (A), diffusion-weighted imaging (B), and positron emis-
sion tomography with fludeoxyglucose F 18 (C). Arrows indicate tumor
images on diffusion-weighted imaging and positron emission tomography.
Minimum value of apparent diffusion coefficient, maximum standard up-
take value, and contrast ratio of standard uptake value in tumor are 0.98
3 103 mm2/s, 3.2, and 0.68, respectively.442 The Journal of Thoracic and Cardiovascular Surcharacteristic curves for the benign versus malignant dis-
crimination showed the optimal cutoff value of ADC on
DWI to be 1.2 3 103 mm2/s and the optimal cutoff value
of SUVCR on PET to be 0.31 on PET.
Among the 96 NSCLC nodules, DWI results were posi-
tive for 70 and negative for 26, whereas PET results were
positive for 69 and negative for 27 (Table 2). Among the
57 well-differentiated adenocarcinomas, 24 (42%) and 25
(44%) had negative results on DWI and PET, respectively.
None of the 5 poorly differentiated adenocarcinomas, l7
squamous cell carcinomas, and 3 adenosquamous carcino-
mas had negative results on either DWI or PET. Among
the 28 benign nodules, DWI results were positive for 1
and negative for 27, whereas PET results were positive for
5 and negative for 23 (Table 3).
Tables 4 and 5 show the results achieved with the McNe-
mar test. Table 4 shows the correlation between DWI and
PET in diagnosis of NSCLC. There was no significant differ-
ence in sensitivity between DWI and PET (P>.999). Table 5
shows the correlation between DWI and PET in diagnosis of
benign nodules. There was no significant difference in spec-
ificity between DWI and PET (P ¼ .22). The accuracies of
DWI and PET were 0.78 and 0.74, respectively, with no sig-
nificant difference (P ¼ .69). Positive predictive values of
DWI and PET were 0.98 and 0.93, respectively, also with
no significant difference (P ¼ .83). Negative predictive
values of DWI and PET were 0.51 and 0.46, respectively,
again with no significant difference (P ¼ .31).
TABLE 2. Findings of diffusion-weighted imaging and positron
emission tomography in non–small cell lung cancer
DWI PET
Histologic type Positive Negative Positive Negative Total
Adenocarcinoma
Well differentiated 33 24 32 25 57
Moderately differentiated 12 2 12 2 14
Poorly differentiated 5 0 5 0 5
Squamous cell carcinoma 17 0 17 0 17
Adenosquamous carcinoma 3 0 3 0 3
Total 70 26 69 27 96
DWI, Diffusion-weighted imaging; PET, positron emission tomography.
TABLE 3. Findings of diffusion-weighted imaging and positron
emission tomography in benign pulmonary nodules
DWI PET
Histologic type Positive Negative Positive Negative Total
Inflammation
Acute 1 3 4 0 4
Chronic 0 20 0 20 20
Hamartoma 0 2 0 2 2
Others 0 2 1 1 2
Total 1 27 5 23 28
DWI, Diffusion-weighted imaging; PET, positron emission tomography.gery c August 2009
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with their relationships to the pathologic tumor stage, tumor
invasiveness of NSCLC, and histologic differentiation in ad-
enocarcinoma. Although DWI did not show the significant
difference of the mean value of ADC in these subgroups,
PET showed a significant difference in SUVCR between
NSCLC at pathologic stage IA versus IB or more advanced
stages; between NSCLC with and without lymphatic,
vascular, and pleural involvements; and between well-dif-
ferentiated and moderately or poorly differentiated adeno-
carcinomas (P<.01–.001).
DISCUSSION
In this study, sensitivity and specificity for differentiating
between NSCLC and benign pulmonary nodules were not
different between DWI and PET. We therefore conclude
that DWI can be used in place of PET for discrimination
between benign and NSCLC lesions.
On the other hand, DWI could not predict the aggressive-
ness of NSCLC, including adenocarcinoma, as well as did
PET. It has been reported that FDG-PET can predict the ag-
TABLE 4. Correlation between diffusion-weighted imaging and
positron emission tomography for diagnosing non-small cell lung
cancer
PET
DWI True positive False negative Total
True positive 61 9 70
False negative 8 18 26
Total 69 27 96
Sensitivity of diffusion-weighted imaging 0.73 (95% confidence interval 0.64–0.82);
sensitivity of positron emission tomography 0.72 (95% confidence interval 0.63–
0.81); P> .999 by McNemar test. DWI, Diffusion-weighted imaging; PET, positron
emission tomography.The Journal of Thoracic andgressiveness of NSCLC15-18 because tumors with low
aggressiveness have low rate of glucose metabolism. We
previously reported that the FDG uptake could be used to
predict the aggressiveness of lung adenocarcinoma; that is,
lung adenocarcinomas with high FDG uptake had more fre-
quent lymph node metastasis, higher tumor invasiveness,
higher proliferative activity, and poorer prognosis than those
with low FDG uptake.16-18 Because ADC in DWI of tumors
is known to decrease with increased cellularity, larger nu-
clei, and larger nuclear/cytoplasmic ratio,4,5 we initially
hypothesized that ADC might correlate with the aggressive-
ness of NSCLC as well as does FDG uptake in PET. In brain
glioma and astrocytoma, Murakami and associates5 reported
that ADC showed a significant correlation with the histo-
logic grade of malignancy and prognosis, supporting our
hypothesis. In this study, however, ADC in DWI did not
show a significant correlation with pathologic tumor stage
and tumor invasiveness of NSCLC or with histological dif-
ferentiation of adenocarcinoma, whereas FDG uptake in
PET did. We therefore conclude that although DWI can im-
age NSCLC as well as does PET, it cannot predict the
TABLE 5. Correlation between diffusion-weighted imaging and
positron emission tomography for diagnosing benign pulmonary
nodules
PET
DWI True negative False positive Total
True negative 23 4 27
False positive 0 1 1
Total 23 5 28
Specificity of diffusion-weighted imaging 0.96 (95% confidence interval 0.90–1.03);
specificity of positron emission tomography 0.82 (95% confidence interval 0.68–
0.96); P ¼ .22 by McNemar test. DWI, Diffusion-weighted imaging; PET, positron
emission tomography.TABLE 6. Correlation between tumor aggressiveness and minimum value of apparent diffusion coefficient and contrast ratio of standard uptake
value
DWI PET
Tumor aggressiveness No. of tumors ADC P value SUVCR P value
Tumor stage .08 <.001
IA 75 1.00  0.34 0.45  0.27
IB-IV 21 0.83  0.20 0.74  0.16
Lymphatic invasion .12 <.01
Negative 79 0.98  0.34 0.46  0.27
Positive 17 0.77  0.18 0.75  0.15
Vascular invasion .08 <.001
Negative 74 0.99  0.37 0.41  0.26
Positive 22 0.85  0.16 0.78  0.14
Pleural involvement .42 <.001
Negative 80 0.97  0.35 0.44  0.27
Positive 16 0.84  0.16 0.78  0.14
Adenocarcinoma histologic differentiation (n ¼ 76) .11 <.001
Well differentiated 57 1.04  0.37 0.38  0.24
Moderately or poorly differentiated 19 0.89  0.22 0.61  0.25
DWI, Diffusion-weighted imaging; PET, positron emission tomography; ADC, minimum value of apparent diffusion coefficient; SUVCR, contrast ratio of standard uptake value.Cardiovascular Surgery c Volume 138, Number 2 443
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particular.
Two reasons might explain why ADC in NSCLC did not
correlate with the tumor aggressiveness, differing from the
results in brain glioma and astrocytoma.5 (1) The difference
in magnetic susceptibility at the tumor–lung interface creates
inhomogeneity in the local magnetic field, which disrupts
the MR signals of lung tumors, like the artifacts that arise
from the heart–lung interface.26 (2) Respiratory and cardiac
motion causes additional image artifacts and signal loss.27
One of the deficiencies of FDG-PET in diagnosis of lung
cancer is its FN rate for well-differentiated adenocarci-
nomas, which is related to their low rate of glucose metabo-
lism and low density.19 In this study, both DWI and PET had
negative results for approximately 40% of well-differenti-
ated adenocarcinomas, suggesting that DWI does not com-
pensate for the PET deficiency in this regard. We therefore
consider well-differentiated adenocarcinomas difficult to
diagnose with either PET or DWI.
Although SUV has frequently been used for evaluation of
FDG-PET, it is well known that several factors can affect the
SUV, such as body size28 and blood glucose level.29We pre-
viously compared the results of SUVmax, SUVCR with con-
tralateral lung, and SUVCR with cerebellum for pulmonary
nodules and reported that SUVCR with contralateral lung
or cerebellum showed significantly higher sensitivity than
did SUVmax,
20 a conclusion supported by Obrzut and co-
workers.30 We therefore selected SUVCR with contralateral
lung for analysis in this study.
Although FDG-PET is useful for imaging the whole body,
DWI does not have that capability, because of the need for
breath holding by the patient during the imaging. Recently,
Takahara and colleagues3 developed a new technology of
DWI that can be conducted under normal breathing conditions
and allows acquisition ofmore sliceswithmultiple signal aver-
aging, higher signal-to-noise ratio, andhigh-qualitymaximum-
intensity projection images,3 enabling whole-body imaging.11
Ohno and colleagues14 recently reported thatwhole-bodyMRI
withDWI showed similar sensitivity forMstaging to PETwith
CT. We have also reported that DWI can be used in place of
PET with CT for N staging of NSCLC.31 ADC in DWI is
known to vary among MR machines, however, so as the next
step a multicenter study should be conducted to determine
whether whole-body DWI can be used for imaging of the
systemic metastasis in lung cancer, as is FDG-PET.
This study showed that DWI can be used in place of PET
for imaging NSCLC. It should be kept in mind, however,
that DWI cannot predict the aggressiveness of NSCLC as
well as FDG-PET does.
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